Ram Devireddy, assistant professor of mechanical engineering at LSU, recently co-authored an article with Todd Monroe, assistant professor of biological and agricultural engineering, investigating the complex effects of nanoparticles on cell freezing. The report was published in the prestigious journal Nanotechnology.
Stephanie Lebret completed the study for her PhD at Deakin?s Centre for Cellular and Molecular Biology under the supervision of Associate Professor Leigh Ackland.
Arsenic exposure appears to continue causing lung and bladder cancer deaths years after exposure ends, according to a study published online June 12 in the Journal of the National Cancer Institute.
Carriers of a BRCA2 variation specific to Iceland are more likely to develop aggressive and lethal prostate cancer than noncarriers, according to a study published online June 12 in the Journal of the National Cancer Institute.
A team led by Horst Kunst at the University of Mainz has found a way to bind a molecule that is typical for tumors to a carrier protein without irritating the immune system. As they report in the journal Angewandte Chemie, their method is based on an immunocompatible connection by way of a sulfur atom, namely, a thioether.
Biovest International, Inc. (OTCBB: BVTI), a majority owned subsidiary of Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) announces a milestone in its effort to gain accelerated conditional approval for BiovaxID?. The independent Data Monitoring Committee (DMC) has requested an interim analysis of all primary and secondary endpoints.
Simple steps, like giving breast cancer survivors an exercise workbook or step pedometer, can improve their quality of life and fatigue levels.
Patients with advanced-stage cancer experience very poor sleep quality and often have troubling staying awake, says Emory University researcher Kathy Parker, PhD, RN.
According to a new GfK Roper Public Affairs survey sponsored by CancerCare, a national nonprofit cancer support organization, while the majority (76 percent) of women surveyed said they know at least a fair amount about breast cancer, many remain unaware of the important recent progress made in treatment.
Virginia Commonwealth University Massey Cancer Center researchers have uncovered a new mechanism of action of the anti-cancer drug sorafenib, which could stimulate the development of novel regimens in which it is combined with other molecularly targeted agents for patients with blood cancers and solid tumors.